Our International Kidney Cancer Patient Charter was created to ensure that the more than one million people living with kidney cancer worldwide have access to the best available treatment, care, information and support. The Charter is based on a survey extended to 34 patient group leaders with a special interest in kidney cancer, located in 20 countries spread over 6 continents.
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. Read more
Dose escalation of tyrosine kinase inhibitors (TKIs) after disease progression in patients with metastatic renal cell carcinoma (mRCC) can lead to a decrease in tumour burden and extend duration of therapy, according to a study. Read more
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC), according to Dr Basma Greef, of the department of oncology at the Cambridge University Hospitals NHS Foundation Trust in the United Kingdom. She and her co-author, professor Tim Eisen, published an article in the British Journal of Cancer suggesting that researchers are introducing a renaissance of immunotherapy in the treatment of RCC. Read more
SAVE THE DATE for our next Expanding Circles conference
6th to 8th April 2017 in Warsaw, Poland
Further information coming soon
6th International Conference for Organisations Representing Patients with Kidney Cancer
14th -16th April 2016
50 kidney cancer advocates from 25 countries met in Chantilly, Paris for our 6th international conference for organisations representing patients with kidney cancer.
The keynote address was delivered by Dr. Bernard Escudier of France, one of the leading kidney cancer specialists in the world. During our conference we were honoured to hear from many other well respected clinicians and experts